Biofil Chemicals & Pharmaceuticals Ltd.

43.60 -0.60 ▼-1.4%

06 June 2023, 04:01:00 PM
Volume: 4,920

Company Profile

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.biofilgroup.net
Market Cap 71.67 Cr.
Enterprise Value(EV) 71.44 Cr. 2023-03
Financial Indicators
Earnings per share (EPS) 0.34 Trailing Twelve Months Ending 2023-03
Price-Earning Ratio (PE) 127.75 Trailing Twelve Months Ending 2023-03
Industry PE 33.76 Trailing Twelve Months Ending 2023-03
Book Value / Share 10.63 Trailing Twelve Months Ending 2023-03
Price to Book Value 4.14 Calculated using Price: 44.04
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 1.63 Cr. 16,273,800 Shares
FaceValue 10
About Biofil Chemicals & Pharmaceuticals Ltd.
Biofil Chemicals & Pharmaceuticals established in 1985, is part of Cyano Group of Industries. The company is into manufacturing of drugs in area of anti-bacterial, analgesics/antipyretics, anti-malarial, anti-psychotics, anti asthmatic/bronchodilators, diuretics, tranquilizer/hypnotics, anti inflammatory, analgesic/antipyretics, anti inflammatory steroids and eye/ear drops

Biofil Chemicals & Pharmaceuticals Ltd. Delivery

Delivered Qty
Traded Qty

Biofil Chemicals & Pharmaceuticals Ltd. Performance

1 Day
-1.36%
1 Week
-3.20%
1 Month
-2.35%
3 Month
-2.42%
6 Month
-22.28%
1 Year
-21.65%
2 Year
-37.67%
5 Year
+224.16%
10 Year
+1996.15%

Biofil Chemicals & Pharmaceuticals Ltd. Fundamental Ratios

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 13.53 13.47 13.28 18.09 3.64 3.60 8.46 8.01 4.24
Return on Capital Employed (%) 12.09 12.97 14.04 21.86 5.13 5.06 10.12 12.18 6.23
Return on Assets (%) 3.68 4.14 4.13 7.81 2.05 1.99 3.63 3.28 2.69

Biofil Chemicals & Pharmaceuticals Ltd. Balance Sheet

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03* Rs. Cr.
Shh. Funds 8 8 11 13 13 14 15 16 17 17
Non Curr. Liab. 0 0 0
Curr. Liab. 7 5 13 9 11 11 27 17 1 14
Minority Int.
Equity & Liab. 15 14 24 22 24 24 42 33 19 31
Non Curr. Assets 9 9 9 9 9 10 10 10 9 9
Curr. Assets 5 5 15 13 15 14 32 23 9 22
Misc. Exp. not W/O
Total Assets 15 14 24 22 24 24 42 33 19 31

Biofil Chemicals & Pharmaceuticals Ltd. Profit and Loss

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. TTM
Net Sales 7 6 13 13 12 23 30 36 22 30
Other Income 0 0 1 0 0 0 0 1 0 0
Total Income 7 6 14 14 12 23 30 37 23 30
Total Expenditure -6 -5 -12 -11 -11 -22 -28 -34 -21 -29
PBIDT 1 1 1 3 1 1 2 2 1 1
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Taxation 0 0 0 -1 0 0 0 -1 0 0
Exceptional Items
PAT 1 1 1 2 0 0 1 1 1 1
Adjusted EPS 0 0 0 1 0 0 1 1 0 0

Biofil Chemicals & Pharmaceuticals Ltd. Cash Flow

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 1 0 1 1 1 0
Cash Fr. Inv. 0 0 0 0 0 0 -1 0 0 0
Cash Fr. Finan. 0 0 0 0 0 0 0 -1 -1 0
Net Change 0 0 0 0 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0 0 0

Biofil Chemicals & Pharmaceuticals Ltd. Shareholding Pattern

9 Qtrs 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%)
Promoter 46.82 46.82 46.82 46.82 46.82 46.82 46.82 46.82 46.82
Public 53.18 53.18 53.18 53.18 53.18 53.18 53.18 53.18 53.18
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Biofil Chemicals & Pharmaceuticals Ltd. Announcements

Wed, 31 May 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
In terms of Regulation 47 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 please find enclosed the public notice published in newspapers i.e. Free press Mumbai & Indore (in English) and Choutha Sansar (in Hindi) on 31st May 2023 regarding Audited Financial Results for the quarter and year ended 31st March 2023 in terms of Regulation 33 of SEBI ((Listing Obligations and Disclosure Requirements) Regulations 2015 to consider and approve the Audited Financial Results for the Quarter and year ended 31st March 2023 along with Auditors Report Statement of Assets and Liabilities and Cash Flow Statement.
Tue, 30 May 2023
Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday 30Th May 2023 Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.
Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 the Company hereby submits Outcome of the Board Meeting held on Tuesday 30 May 2023 for the purpose of consideration and approval of Audited Financial Results of the Company for the quarter and year ended 31st March 2023 along with the Auditors Report thereon and consideration of other matters.
Tue, 30 May 2023
Submission Of Audited Financial Results For The Quarter As Well As Year Ended 31St March 2023 In Terms Of Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are here enclosing the Audited Financial Results for the quarter as well as year ended 31st March 2023 duly approved by the Board of Directors at its meeting held today i.e. Tuesday 30th May 2023 together with Audit Report thereon Statement of assets and liabilities Cash Flow Statement & declaration by the Managing Director of Company pursuant to second proviso of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Biofil Chemicals & Pharmaceuticals Ltd. Technical Scans

Tue, 06 Jun 2023
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
S Making Higher Highs for 2 Days
High Decrease in 6 Months High Decrease in 6 Months
High Increase in 5 Years High Increase in 5 Years

Biofil Chemicals & Pharmaceuticals Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 243,184.60 1,013.55 +0.4%
Divi's Laboratories Ltd. 93,886.95 3,536.65 +2.2%
Cipla Ltd. 78,522.76 972.75 -0.2%
Dr. Reddy's Laboratories Ltd. 77,195.89 4,635.15 +0.7%
Apollo Hospitals Enterprise Ltd. 71,115.89 4,946.00 0.0%
Torrent Pharmaceuticals Ltd. 60,794.95 1,796.30 +1.2%
Mankind Pharma Ltd. 59,699.70 1,490.30 +4.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 28.70 1,013.55 +0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 51.49 3,536.65 +2.2%
Cipla Ltd. Consolidated 2023-03 28.02 972.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 17.13 4,635.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 86.83 4,946.00 0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 48.83 1,796.30 +1.2%
Mankind Pharma Ltd. Standalone 2022-03 44.71 1,490.30 +4.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 4.34 1,013.55 +0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 7.35 3,536.65 +2.2%
Cipla Ltd. Consolidated 2023-03 3.35 972.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 3.32 4,635.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 11.49 4,946.00 0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9.81 1,796.30 +1.2%
Mankind Pharma Ltd. Standalone 2022-03 5.75 1,490.30 +4.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,013.55 +0.4%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,536.65 +2.2%
Cipla Ltd. Consolidated 2022-03 0.04 972.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,635.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,946.00 0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,796.30 +1.2%
Mankind Pharma Ltd. Standalone 2022-03 0.14 1,490.30 +4.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,013.55 +0.4%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,536.65 +2.2%
Cipla Ltd. Consolidated 2022-03 13.10 972.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,635.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,946.00 0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,796.30 +1.2%
Mankind Pharma Ltd. Standalone 2022-03 26.72 1,490.30 +4.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,013.55 +0.4%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,536.65 +2.2%
Cipla Ltd. Consolidated 2022-03 13.10 972.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,635.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,946.00 0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,796.30 +1.2%
Mankind Pharma Ltd. Standalone 2022-03 26.72 1,490.30 +4.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,013.55 +0.4%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,536.65 +2.2%
Cipla Ltd. Consolidated 2022-03 21,763.34 972.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,635.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,946.00 0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,796.30 +1.2%
Mankind Pharma Ltd. Standalone 2022-03 7,781.56 1,490.30 +4.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,013.55 +0.4%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,536.65 +2.2%
Cipla Ltd. Consolidated 2022-03 2,559.47 972.75 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,635.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,946.00 0.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,796.30 +1.2%
Mankind Pharma Ltd. Standalone 2022-03 1,452.96 1,490.30 +4.6%

Biofil Chemicals & Pharmaceuticals Ltd. FAQ's

What is Biofil Chem & Pharma share price?

Can I buy Biofil Chem & Pharma shares now?

What is the Market Cap of Biofil Chem & Pharma?

What are the key metrics to analyse Biofil Chem & Pharma?

What is the 52 Week High and Low of Biofil Chem & Pharma?

What is the trend of Biofil Chem & Pharma share price?